Zhitong Finance App News, Hejing Biotech (688068.SH) announced that recently, the first clinical study on the indications of the innovative drug SGC001 injection “expected severe acute pancreatitis” independently developed by Beijing Shunjing Biomedical Technology Co., Ltd. (“Shunjing Pharmaceutical”), the holding subsidiary of the company, completed the first case of enrolling the subjects.

Zhitong Finance App News, Hotjing Biotech (688068.SH) announced that recently, the first clinical study on the indications of the innovative drug SGC001 injection “expected severe acute pancreatitis” independently developed by Beijing Shunjing Biomedical Technology Co., Ltd. (“Shunjing Pharmaceutical”), a holding subsidiary of the company, completed the first case of enrolling the subjects.